drugset
Drugs / VLS-1488
last change Jun 2026 re-read 3 minutes ago

VLS-1488

targets KIF18A via inhibition

Developed for
endometrium neoplasm · head and neck squamous cell carcinoma · non-small cell squamous lung carcinoma · ovarian carcinosarcoma · ovarian serous adenocarcinoma · triple-negative breast carcinoma · uterine carcinosarcoma
Investigated by
Volastra Therapeutics, Inc.

Trials 1

today NCT05902988 · Ph 1/2
202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05902988 Oct 2023 → Jun 2026 overdue endometrium neoplasm, head and neck squamous cell carcinoma, non-small cell squamous lung carcinoma, ovarian carcinosarcoma +3 Volastra Therapeutics, Inc. Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as VLS-1488 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05902988 ↗
Action Inhibit “an Oral KIF18A Inhibitor” NCT05902988 ↗
Route Oral “VLS-1488 tablets will be given orally.” NCT05902988 ↗
Target KIF18A “an Oral KIF18A Inhibitor” NCT05902988 ↗